Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Precision BioSciences Inc DTIL

Healthcare Biotechnology
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene... see more

Recent & Breaking News (NDAQ:DTIL)

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 4 days ago

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Business Wire 8 days ago

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

Business Wire 13 days ago

Precision BioSciences to Report First Quarter Results on May 13, 2024

Business Wire 13 days ago

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE's Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

Business Wire May 7, 2024

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024

Business Wire May 1, 2024

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

Business Wire April 16, 2024

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Business Wire March 27, 2024

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024

Business Wire March 20, 2024

Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy

Business Wire March 19, 2024

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Business Wire March 6, 2024

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants

Business Wire March 1, 2024

Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants

Business Wire February 29, 2024

Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences

Business Wire February 20, 2024

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness

Business Wire February 14, 2024

Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations

Business Wire February 13, 2024

Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases

Business Wire February 12, 2024

Precision BioSciences to Effect a Reverse Stock Split

Business Wire February 9, 2024

TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases

GlobeNewswire January 9, 2024

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

Business Wire January 9, 2024